Status:
COMPLETED
Cadmium-zinc-telluride (CZT) Imaging of Myocardial Blood Flow (MBF) (SPECT MBF)
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Collaborating Sponsors:
GE Healthcare
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study is being done to compare the blood flow measurements obtained with the SPECT and PET imaging scans. Measurements such as myocardial blood flow (MBF) and myocardial flow reserve (MFR) are an...
Detailed Description
Absolute myocardial blood flow (MBF) and myocardial flow reserve (MFR) are calculated measurements that are obtained using positron emission tomography (PET) nuclear imaging, from a myocardial perfusi...
Eligibility Criteria
Inclusion
- For all participants
- Age ≥ 18 years old
- BMI ≤ 40 kg/m2
- Able and willing to comply with the study procedures
- Written informed consent Participants with intermediate to high probability of CAD
- Suspected or known CAD on a stable medication regime. Healthy volunteers without known heart disease
- Low risk of CAD (ACC Guidelines Pre-test Probability of Coronary Disease by Symptoms, Gender and Age)
Exclusion
- History or risk of severe bradycardia (heart rate \< 50 beats per minute) not related to chronotropic drugs
- Known second- or third-degree AV block without pacemaker
- Dyspnea (NYHA III/IV), wheezing asthma or COPD
- Coronary artery bypass graft (CABG) surgery within 60 days prior to screening or at any time after consent
- Percutaneous coronary intervention (PCI) within 30 days prior to screening or at any time following consent
- Acute myocardial infarction or acute coronary syndrome within 60 days prior to screening or at any time following consent
- Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox)
- Known hypersensitivity to dipyridamole
- Breastfeeding or pregnancy
- Claustrophobia or inability to lie still in a supine position
- Unwillingness or inability to provide informed consent
Key Trial Info
Start Date :
October 30 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 2 2022
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT02280941
Start Date
October 30 2014
End Date
September 2 2022
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7